FDA
-
-
-
-
-
-
-
Anika Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Anika Therapeutics (ANIK) Completes Divestiture of Parcus Medical
-
-
-
-
-
-
-
Anika Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
-
-
-
-
-
-
-
Anika Therapeutics (ANIK) completes enrollment in Phase III clinical study for Hyalofast
-
-
-
-
-
-
-
Anika Therapeutics (ANIK) Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
-
-
-
-
-
-
-
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

